More good news from HCM and the share price not responding. Been an "opportunity cost" hold, but one day it may reward.
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
– First and only EZH2 inhibitor approved by the NMPA –
– HUTCHMED’s fourth product, and its first approval in hematological malignancies – |
And the share price is now lower than it was on the first day of 2025 - guffaw!! |
Sales were slightly better than I expected, with the share of revenue from Takeda rising from 33% to 38% (maybe some pre-orders to beat Trump tariffs.
The Inmagene reverse takeover of Ikena will leave HCM with a 3% stake in the enlarged entity.
They will have a post tax profit of $400m in 2025 from the disposal….and yet still no reward for shareholders. |
"Net income of $37.7 million was achieved in 2024, with a cash balance of $836.1 million as of December 31, 2024, achieving financial self-reliance ahead of schedule"
"The proceeds from the SHPL disposal, on top of the ongoing profits of our globally commercialized portfolio, enables us to expedite the roll-out of this differentiated platform, which will be key to our long-term value creation". |
Not a bad start to results day.
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China...
The combination of fruquintinib and sintilimab received conditional approval from the China National Medical Products Administration (“NMPA”) for the treatment of patients with advanced endometrial cancer with Mismatch Repair proficient (pMMR) tumors that have failed prior systemic therapy and are not candidates for curative surgery or radiation, based on data from the FRUSICA-1 study. |
Dominant shareholder CKHH will be flush with cash later this year as it is negotiating the sale of its ports to Blackrock and others. The deal will generate about US$19bn for CKHH. Plenty of firepower if they want to take HCM private or support M&A. |
2024 could be profitable depending on the release of the upfront Takeda fee into revenue.
2025 will be profitable if the JV sale transaction goes through. There will not be much advance in China sales, but global royalties from Takeda will increase (could double)
2026 may see revenue progression from Savolitinib and Sovleplenib if approved at which point the underlying business may be profitable going forward. |
20 Feb 2025: HUTCHMED (HCM) Upgraded to Buy: Here's Why |
I have created a CKI thread for further discussion of CKHH and CKI matters that may not be of interest to Hutchmed shareholders. |
I don’t doubt Trump wants more money to flow to the US from Panama, but the threat from a commercial port company is minimal, it is not as if there is a division of the PLA on site - they are probably struggling to be profitable and increased tariffs will do nothing to improve throughput. There have also been ‘climate change’ articles commenting on low water levels in the lake part of the canal which have threatened to close the route to the ships with deeper draughts.
The date for teh results has been set as 19 March which is nearly three weeks further into the year than previously. There does not seem to be a good reason for the later date….but it will be in the pack of CK results rather than an early outlier. |
A bit more about the Panama Canal malarkey with various references to 'CK Hutchison'. It's from 'BBC Verify' - just as bad / ridiculous as their 'disinformation' correspondent - but I am guessing that its publication is to serve some purpose. |
 Mcmather - sentiment towards HK/China is poor in the west. No doubt HK/China is sceptical of the value of western operations represented in HK companies. So CKHH gets a double negative view. CKHH as a conglomerate trades at a hefty discount - if you add the market value of its listed subs you get the mcap of the parent. One might think the logical answer is a break up and realisation of the value of the assets…….
There is little synergy within the CK group of companies for Hutchmed to exploit and it seems to have been on its own for a while with CKHH selling down to under 40%.
Hutchmed seems to be inhabiting a nether world where it has grown into a commercial organisation, but its larger competitors are interested in smaller bolt on acquisitions. Eventually the mid sized companies will need to huddle together to avoid being preyed upon or accept they will be only a bit part player in the background.
The Sovlep manufacturing issue is just the latest in a steady flow of mis-steps. I think it is time for Victor to make a trade in HCM. |
Double yer money from here...
"Feb. 11, 2025, 09:25 AM
BofA raised the firm’s price target on Hutchmed (HCM) to $27 from $26 and keeps a Buy rating on the shares. While noting it sees “some regulatory headwinds potentially ahead,” the firm keeps a Buy rating on the shares and cites higher revenue expectations for key assets after “strong performance in 2024” for its revised price target" |
AZ reported 2024 sales of Orpathys of $46m. This is flat for the year, and up 2% at CER.
The expansion to 1L should give this a boost, but the key is getting the SACHI and SAVANNAH combo with Tagrisso approved during 2025. There is no news on the FDA application - it did have breakthrough designation allowing a rolling submission - surely the submission is nearly complete after which I anticipate a PDUFA date of a further 6-9 months.
The China combination is not expected to be before the US approval (per the company timeline for product launches), but both Tagrisso and Savolitinib are individually approved, so we might expect something closer to the 7 months for the EMC combo than a 12-16m typical approval. |
A constant drip drip of selling since the end of October. |
HUTCHMED Announces Delay in Circular Dispatch for Major Transaction
TipRanks UK Auto-Generated Newsdesk
Jan 28, 2025, 10:02 AM
Story Highlights
HUTCHMED plans to divest a 45% stake in Shanghai Hutchison Pharmaceuticals.
The dispatch of transaction details is postponed until February 28, 2025.
HUTCHMED (China) Limited ( HK:0013 -1.42% ▼ ) just unveiled an announcement.
HUTCHMED (China) Limited announced a major transaction involving the disposal of a 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited, valued at US$608 million. The dispatch of the circular detailing this transaction has been delayed until February 28, 2025, due to additional time needed by GP Health Service Capital to finalize details. This delay is attributed to the Chinese New Year holidays, and stakeholders are advised to exercise caution regarding the deal’s completion, as it is contingent on the satisfaction of certain conditions.
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company dedicated to the discovery and global development and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully brought its first three cancer medicines to market in China, with one also approved in the US, Europe, and Japan.
YTD Price Performance: -6.81%
Average Trading Volume: 55,198
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £1.88B
TipRanks’ Stock Analysis page. |
RNS Number : 9427U
Hutchmed (China) Limited
28 January 2025
Overseas Regulatory Announcement -
Disposal Transaction
HUTCHMED (China) Limited ("HUTCHMED") notes the below text, which is from an announcement released to the Stock Exchange of Hong Kong Limited on January 28, 2025 pursuant to Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The text relates to the dispatch timing of the extraordinary general meeting circular that relates to the transaction described in the announcement dated January 2, 2025, entitled "HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture".
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial‑stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing cancer drug candidates from in‑house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
CONTACTS
Investor Enquiries
+852 2121 8200 / ir@hutch-med.com |
It does seem Tacked can get approvals for Fruzaqla wherever it wants….but what is key is the prices being negotiated for access to state funded healthcare systems. Spain was the first in the EU in December, the UK decision is due in early March. Only once these negotiations are complete will there be significant sales.
Takeda reports Oct-Dec sales on Thursday 30 Jan. The 2024 sales by quarter in USD were 50/80/75m. Q3 may be lowered by fewer hospital appts over the summer. Tak started sales in JPN and EU during H2, I am expecting a result in the 80-100m range with a bias towards 85-90m as most likely. |
A bit of news from Monday:
“Takeda Canada Reports Market Authorization For FRUZAQLA In Canada - Quick Facts
January 20, 2025 — 08:11 am EST”
More here; |
Last hour:
"Innovent Biologics ( HK:1801 -10.31% ▼ ) has issued an announcement.
Innovent Biologics has reported unusual price and trading volume movements in its shares but confirmed no changes in its business operations or any undisclosed information". |
Can but laugh - from yesterday's UK close to the price earlier, circa £230m wiped off the market cap. |
Followed by a near 10% fall in HK on no further news…. |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
